Pfizer’s ABRYSVO® Shows Promising Results in Phase 3 Trial Targeting RSV Prevention in High-Risk Adults
Pfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read morePfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read moreThe cutting-edge Dynamic Light Scattering (DLS) Particle Size Analyzer is a powerful benchtop device that enables precise particle size determination in
Read moreModerna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read moreGERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
Read moreThe opening of Catalent’s new ultra-modern, commercial-scale plasmid DNA (pDNA) manufacturing facility in Gosselies, Belgium was announced on the 26th
Read moreModerna Inc will make investments in mRNA research and development (R&D) in the UK and construct a cutting-edge facility for
Read moreAmerican biotech Oragenics, Inc. announced on Thursday the posting of a preprint manuscript in bioRxiv (pronounced “bio-archives”) evaluating a novel
Read moreThe U.S. Food and Drug Administration (FDA) has approved a second COVID-19 vaccine developed by Moderna, which will be marketed
Read morePfizer and BioNTech announced on Tuesday that a clinical trial in healthy people 18 to 55 years old to assess
Read moreVaccine maker Moderna, which is at the forefront of developing messenger RNA (mRNA) therapeutics and vaccines, announced today that according
Read more